Vascular Biogenics (NASDAQ:VBLT) Receives New Coverage from Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Vascular Biogenics (NASDAQ:VBLT – Get Rating) in a report issued on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Vascular Biogenics Trading Up 18.7 %

Shares of Vascular Biogenics stock opened at $0.19 on Thursday. Vascular Biogenics has a twelve month low of $0.10 and a twelve month high of $2.20. The stock has a market capitalization of $13.09 million, a P/E ratio of -0.39 and a beta of 0.82. The business’s fifty day moving average price is $0.15 and its 200 day moving average price is $0.16.

Institutional Trading of Vascular Biogenics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Group One Trading L.P. grew its holdings in shares of Vascular Biogenics by 62.0% during the third quarter. Group One Trading L.P. now owns 293,118 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 112,148 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of Vascular Biogenics during the third quarter valued at approximately $52,000. Telemetry Investments L.L.C. grew its holdings in shares of Vascular Biogenics by 239.0% during the third quarter. Telemetry Investments L.L.C. now owns 400,000 shares of the biopharmaceutical company’s stock valued at $62,000 after purchasing an additional 282,000 shares during the last quarter. Envestnet Asset Management Inc. bought a new position in shares of Vascular Biogenics during the first quarter valued at approximately $64,000. Finally, Two Sigma Investments LP acquired a new position in shares of Vascular Biogenics during the third quarter worth approximately $66,000. 4.81% of the stock is owned by hedge funds and other institutional investors.

About Vascular Biogenics

(Get Rating)

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.